Verastem Oncology’s pipeline is focused on novel small molecule drugs that seek to treat cancer by inhibiting critical signaling pathways that promote cancer cell survival and tumor growth.

    • RAF/MEK
    • Focal adhesion kinase (FAK)
    • Phosphoinositide 3-kinase (PI3K) delta and gamma




Verastem Pipeline FAK January 2020


PI3K Delta Gamma


Pipeline Verastem Oncology


These studies are investigating treatments or outcomes that have not received approval from a Health Authority. There is no guarantee that the outcome of these studies will result in approval.